Georg encouraged by successful male birth control study
June 18, 2024
A successful first-in-human clinical study of YCT-529, a hormone-free birth control pill for men developed by Dr. Gunda Georg of the College of Pharmacy and YourChoice Therapeutics, demonstrated its safety.
“Numerous published studies and surveys show that the world wants and needs more male contraceptive options. We also can’t deny that women are tired of bearing the burden of hormones,” Georg said in a press release. “Society is ready for a male contraceptive, and we applaud the organizations that recognize this and support our efforts to deliver the first hormone-free male birth control pill.”
Media Contacts
Related Stories
Dr. Melanie Nicol, associate professor and director of graduate studies in the Department of Experimental and Clinical Pharmacology (ECP) received a new award of $3 million across the next five years from the National Institutes of Health (NIH).
Duerfeldt's research is focused on the development of chemical tools that can be utilized to enhance our understanding of disease mechanisms and the development of new therapeutic leads for bacterial infections and ocular diseases.
The Center for Drug Design (CDD), part of the University of Minnesota College of Pharmacy, created a novel technology using biomimetic decoy molecules to boost the skin's natural ability to mitigate ultraviolet-induced damage, a development that has the potential to revolutionize the skincare industry.